Europe Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity
Europe pharmacogenomics market accounted for $1,565.6 million in 2019 and will grow by 7.1% annually over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.
Highlighted with 38 tables and 50 figures, this 125-page report “Europe Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Based on Service, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
23andMe, Inc.
Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Highlighted with 38 tables and 50 figures, this 125-page report “Europe Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
Based on Service, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Genotyping
- SNP Identification
- Diagnostics
- Other Services
- Polymerase Chain Reaction (PCR)
- Microarray
- Sequencing
- Electrophoresis
- Mass Spectrometry
- Other Technologies
- Oncology
- Infectious Diseases
- Neurology/Psychiatry
- Cardiovascular
- Pain Management
- Other Applications
- Hospitals and Clinics
- Pharmaceutical Companies
- Research Institutes
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
23andMe, Inc.
Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 INTRODUCTION
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF EUROPE MARKET BY SERVICE
3.1 Market Overview by Service
3.2 Genotyping
3.3 SNP Identification
3.4 Diagnostics
3.5 Other Services
4 SEGMENTATION OF EUROPE MARKET BY TECHNOLOGY
4.1 Market Overview by Technology
4.2 Polymerase Chain Reaction (PCR)
4.3 Microarray
4.4 Sequencing
4.5 Electrophoresis
4.6 Mass Spectrometry
4.7 Other Technologies
5 SEGMENTATION OF EUROPE MARKET BY APPLICATION
5.1 Market Overview by Application
5.2 Oncology
5.3 Infectious Diseases
5.4 Neurology/Psychiatry
5.5 Cardiovascular
5.6 Pain Management
5.7 Other Applications
6 SEGMENTATION OF EUROPE MARKET BY END USER
6.1 Market Overview by End User
6.2 Hospitals and Clinics
6.3 Pharmaceutical Companies
6.4 Research Institutes
7 EUROPEAN MARKET 2019-2030 BY COUNTRY
7.1 Overview of European Market
7.2 Germany
7.3 UK
7.4 France
7.5 Spain
7.6 Italy
7.7 Russia
7.8 Rest of European Market
8 COMPETITIVE LANDSCAPE
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
23ANDME, INC.
Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.
9 INVESTING IN EUROPE MARKET: RISK ASSESSMENT AND MANAGEMENT
9.1 Risk Evaluation of Europe Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF EUROPE MARKET BY SERVICE
3.1 Market Overview by Service
3.2 Genotyping
3.3 SNP Identification
3.4 Diagnostics
3.5 Other Services
4 SEGMENTATION OF EUROPE MARKET BY TECHNOLOGY
4.1 Market Overview by Technology
4.2 Polymerase Chain Reaction (PCR)
4.3 Microarray
4.4 Sequencing
4.5 Electrophoresis
4.6 Mass Spectrometry
4.7 Other Technologies
5 SEGMENTATION OF EUROPE MARKET BY APPLICATION
5.1 Market Overview by Application
5.2 Oncology
5.3 Infectious Diseases
5.4 Neurology/Psychiatry
5.5 Cardiovascular
5.6 Pain Management
5.7 Other Applications
6 SEGMENTATION OF EUROPE MARKET BY END USER
6.1 Market Overview by End User
6.2 Hospitals and Clinics
6.3 Pharmaceutical Companies
6.4 Research Institutes
7 EUROPEAN MARKET 2019-2030 BY COUNTRY
7.1 Overview of European Market
7.2 Germany
7.3 UK
7.4 France
7.5 Spain
7.6 Italy
7.7 Russia
7.8 Rest of European Market
8 COMPETITIVE LANDSCAPE
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
23ANDME, INC.
Abbott Laboratories
Admera Health, LLC
Agena Biosciences, Inc.
Astra Zeneca PLC
Bayer AG
Becton, Dickinson and Company
Cancer Genetics, Inc.
Dynamic DNA Laboratories
Empire Genomics LLC
F. Hoffmann-La Roche Ltd
geneOmbio Technologies Pvt Ltd.
Genomic Health, Inc.
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics Inc.
Oneome LLC
Opko Health, Inc.
Pathway Genomics Corporation
QIAGEN N.V.
Quest Diagnostics Incorporated
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Transgenomic, Inc.
9 INVESTING IN EUROPE MARKET: RISK ASSESSMENT AND MANAGEMENT
9.1 Risk Evaluation of Europe Market
9.2 Critical Success Factors (CSFs)
Related Reports and Products
LIST OF TABLES
Table 1. Snapshot of Europe Pharmacogenomics Market, 2019-2030
Table 2. Web-based Resources of Pharmacogenomics
Table 3. Main Product Trends and Market Opportunities in Europe Pharmacogenomics Market
Table 4. Europe Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing
Table 6. Europe Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 7. Europe Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry
Table 9. Europe Pharmacogenomics Market by End User, 2019-2030, $ mn
Table 10. Europe Pharmacogenomics Market by Country, 2019-2030, $ mn
Table 11. Germany Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 12. Germany Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 13. Germany Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 14. UK Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 15. UK Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 16. UK Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 17. France Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 18. France Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 19. France Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 20. Spain Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 21. Spain Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 22. Spain Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 23. Italy Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 24. Italy Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 25. Italy Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 26. Russia Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 27. Russia Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 28. Russia Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 29. Pharmacogenomics Market in Rest of Europe by Country, 2019-2030, $ mn
Table 30. Product Approvals by Company, January 2016 – April 2019
Table 31. Breakdown of Europe Market by Key Vendor, 2019, %
Table 32. 23andMe, Inc.: Company Snapshot
Table 33. 23andMe, Inc.: Business Segmentation
Table 34. 23andMe, Inc.: Product Portfolio
Table 35. 23andMe, Inc.: Revenue, 2016-2018, $ mn
Table 36. 23andMe, Inc.: Recent Developments
Table 37. Risk Evaluation for Investing in Europe Market, 2019-2030
Table 38. Critical Success Factors and Key Takeaways
Table 1. Snapshot of Europe Pharmacogenomics Market, 2019-2030
Table 2. Web-based Resources of Pharmacogenomics
Table 3. Main Product Trends and Market Opportunities in Europe Pharmacogenomics Market
Table 4. Europe Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing
Table 6. Europe Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 7. Europe Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry
Table 9. Europe Pharmacogenomics Market by End User, 2019-2030, $ mn
Table 10. Europe Pharmacogenomics Market by Country, 2019-2030, $ mn
Table 11. Germany Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 12. Germany Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 13. Germany Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 14. UK Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 15. UK Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 16. UK Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 17. France Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 18. France Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 19. France Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 20. Spain Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 21. Spain Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 22. Spain Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 23. Italy Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 24. Italy Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 25. Italy Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 26. Russia Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 27. Russia Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 28. Russia Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 29. Pharmacogenomics Market in Rest of Europe by Country, 2019-2030, $ mn
Table 30. Product Approvals by Company, January 2016 – April 2019
Table 31. Breakdown of Europe Market by Key Vendor, 2019, %
Table 32. 23andMe, Inc.: Company Snapshot
Table 33. 23andMe, Inc.: Business Segmentation
Table 34. 23andMe, Inc.: Product Portfolio
Table 35. 23andMe, Inc.: Revenue, 2016-2018, $ mn
Table 36. 23andMe, Inc.: Recent Developments
Table 37. Risk Evaluation for Investing in Europe Market, 2019-2030
Table 38. Critical Success Factors and Key Takeaways
LIST OF FIGURES
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Europe Pharmacogenomics Market, 2019-2030, $ mn
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice
Figure 7. Impact of COVID-19 on Business
Figure 8. Primary Drivers and Impact Factors of Europe Pharmacogenomics Market
Figure 9. World Top 10 Causes of Deaths, 2016
Figure 10. Primary Restraints and Impact Factors of Europe Pharmacogenomics Market
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics
Figure 12. Investment Opportunity Analysis
Figure 13. Porter’s Fiver Forces Analysis of Europe Pharmacogenomics Market
Figure 14. Breakdown of Europe Pharmacogenomics Market by Service, 2019-2030, % of Revenue
Figure 15. Europe Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%)
Figure 16. Europe Pharmacogenomics Market: Genotyping, 2019-2030, $ mn
Figure 17. Europe Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn
Figure 18. Europe Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn
Figure 19. Europe Pharmacogenomics Market: Other Services, 2019-2030, $ mn
Figure 20. Breakdown of Europe Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue
Figure 21. Europe Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%)
Figure 22. Europe Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn
Figure 23. Europe Pharmacogenomics Market: Microarray, 2019-2030, $ mn
Figure 24. Europe Pharmacogenomics Market: Sequencing, 2019-2030, $ mn
Figure 25. Europe Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn
Figure 26. Europe Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn
Figure 27. Europe Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn
Figure 28. Breakdown of Europe Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue
Figure 29. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)
Figure 30. Europe Pharmacogenomics Market: Oncology, 2019-2030, $ mn
Figure 31. Europe Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn
Figure 32. Europe Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn
Figure 33. Europe Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn
Figure 34. Europe Pharmacogenomics Market: Pain Management, 2019-2030, $ mn
Figure 35. Europe Pharmacogenomics Market: Other Applications, 2019-2030, $ mn
Figure 36. Breakdown of Europe Pharmacogenomics Market by End User, 2019-2030, % of Revenue
Figure 37. Europe Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)
Figure 38. Europe Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn
Figure 39. Europe Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn
Figure 40. Europe Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn
Figure 41. Breakdown of European Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue
Figure 42. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 43. Pharmacogenomics Market in Germany, 2019-2030, $ mn
Figure 44. Pharmacogenomics Market in UK, 2019-2030, $ mn
Figure 45. Pharmacogenomics Market in France, 2019-2030, $ mn
Figure 46. Pharmacogenomics Market in Spain, 2019-2030, $ mn
Figure 47. Pharmacogenomics Market in Italy, 2019-2030, $ mn
Figure 48. Pharmacogenomics Market in Russia, 2019-2030, $ mn
Figure 49. Pharmacogenomics Market in Rest of Europe, 2019-2030, $ mn
Figure 50. Growth Stage of Europe Pharmacogenomics Industry over the Forecast Period
COMPANIES MENTIONED
3M Health Care Limited
Adherium Limited
Amiko Digital Health Limited
AsthmaMD
AstraZeneca plc
Boehringer Ingelheim International GmbH
Capsule Technologies, Inc.
Cohero Health
GlaxoSmithKline plc
Kaia Health Software GmbH
Medical International Research (MIR)
Novartis AG
NuvoAir
Reciprocal Labs (Propeller Health)
Sensiron AG
Tactio Health
Teva Pharmaceuticals Industries Ltd.
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Europe Pharmacogenomics Market, 2019-2030, $ mn
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice
Figure 7. Impact of COVID-19 on Business
Figure 8. Primary Drivers and Impact Factors of Europe Pharmacogenomics Market
Figure 9. World Top 10 Causes of Deaths, 2016
Figure 10. Primary Restraints and Impact Factors of Europe Pharmacogenomics Market
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics
Figure 12. Investment Opportunity Analysis
Figure 13. Porter’s Fiver Forces Analysis of Europe Pharmacogenomics Market
Figure 14. Breakdown of Europe Pharmacogenomics Market by Service, 2019-2030, % of Revenue
Figure 15. Europe Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%)
Figure 16. Europe Pharmacogenomics Market: Genotyping, 2019-2030, $ mn
Figure 17. Europe Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn
Figure 18. Europe Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn
Figure 19. Europe Pharmacogenomics Market: Other Services, 2019-2030, $ mn
Figure 20. Breakdown of Europe Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue
Figure 21. Europe Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%)
Figure 22. Europe Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn
Figure 23. Europe Pharmacogenomics Market: Microarray, 2019-2030, $ mn
Figure 24. Europe Pharmacogenomics Market: Sequencing, 2019-2030, $ mn
Figure 25. Europe Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn
Figure 26. Europe Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn
Figure 27. Europe Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn
Figure 28. Breakdown of Europe Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue
Figure 29. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)
Figure 30. Europe Pharmacogenomics Market: Oncology, 2019-2030, $ mn
Figure 31. Europe Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn
Figure 32. Europe Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn
Figure 33. Europe Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn
Figure 34. Europe Pharmacogenomics Market: Pain Management, 2019-2030, $ mn
Figure 35. Europe Pharmacogenomics Market: Other Applications, 2019-2030, $ mn
Figure 36. Breakdown of Europe Pharmacogenomics Market by End User, 2019-2030, % of Revenue
Figure 37. Europe Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)
Figure 38. Europe Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn
Figure 39. Europe Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn
Figure 40. Europe Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn
Figure 41. Breakdown of European Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue
Figure 42. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 43. Pharmacogenomics Market in Germany, 2019-2030, $ mn
Figure 44. Pharmacogenomics Market in UK, 2019-2030, $ mn
Figure 45. Pharmacogenomics Market in France, 2019-2030, $ mn
Figure 46. Pharmacogenomics Market in Spain, 2019-2030, $ mn
Figure 47. Pharmacogenomics Market in Italy, 2019-2030, $ mn
Figure 48. Pharmacogenomics Market in Russia, 2019-2030, $ mn
Figure 49. Pharmacogenomics Market in Rest of Europe, 2019-2030, $ mn
Figure 50. Growth Stage of Europe Pharmacogenomics Industry over the Forecast Period
COMPANIES MENTIONED
3M Health Care Limited
Adherium Limited
Amiko Digital Health Limited
AsthmaMD
AstraZeneca plc
Boehringer Ingelheim International GmbH
Capsule Technologies, Inc.
Cohero Health
GlaxoSmithKline plc
Kaia Health Software GmbH
Medical International Research (MIR)
Novartis AG
NuvoAir
Reciprocal Labs (Propeller Health)
Sensiron AG
Tactio Health
Teva Pharmaceuticals Industries Ltd.
